+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ranibizumab"

Ranibizumab Market - Global Forecast 2026-2032 - Product Thumbnail Image

Ranibizumab Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 196 Pages
  • Global
From
Ranibizumab Market Report 2026 - Product Thumbnail Image

Ranibizumab Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
From
From
Geographic Atrophy Market Report 2026 - Product Thumbnail Image

Geographic Atrophy Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Diabetic Retinopathy Epidemiology Forecast 2026-2035 - Product Thumbnail Image

Diabetic Retinopathy Epidemiology Forecast 2026-2035

  • Report
  • May 2026
  • 100 Pages
  • Global
From
Retinal Vein Occlusion Epidemiology Forecast 2026-2035 - Product Thumbnail Image

Retinal Vein Occlusion Epidemiology Forecast 2026-2035

  • Report
  • May 2026
  • 100 Pages
  • Global
From
From
Diabetic Macular Edema Pipeline Analysis Report 2026 - Product Thumbnail Image

Diabetic Macular Edema Pipeline Analysis Report 2026

  • Report
  • May 2026
  • 150 Pages
  • Global
From
Retinopathy of Prematurity Epidemiology Forecast 2026-2035 - Product Thumbnail Image

Retinopathy of Prematurity Epidemiology Forecast 2026-2035

  • Report
  • May 2026
  • 150 Pages
  • Global
From
Diabetic Eye Disease Epidemiology Forecast 2026-2035 - Product Thumbnail Image

Diabetic Eye Disease Epidemiology Forecast 2026-2035

  • Report
  • May 2026
  • 150 Pages
  • Global
From
From
From
From
Loading Indicator

Ranibizumab is a monoclonal antibody used to treat optical disorders such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). It is administered as an intravitreal injection, and works by inhibiting the activity of vascular endothelial growth factor (VEGF), which is responsible for the growth of abnormal blood vessels in the eye. Ranibizumab is the first anti-VEGF drug approved by the US Food and Drug Administration (FDA) for the treatment of wet AMD, and is now widely used in the treatment of other optical disorders. Ranibizumab is available in both branded and generic forms, and is marketed by a number of pharmaceutical companies, including Novartis, Regeneron, Genentech, and Allergan. Show Less Read more